Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | PARP1 | P09874 | 2/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | F7 | P08709 | 1/20 | 0.59 |
| ▸ | F3 | P13726 | 1/20 | 0.59 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.59 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.59 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.59 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.59 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31228697 | 0.96 | CYP3A4 (0.70) | CYP3A4CYP2C19TSHRPARP1POLB | |
| Benzamide SCHEMBL1679183 | 0.93 | CYP3A4 (0.73) | CYP3A4CYP2C19TSHRPARP1POLB | |
| Benzamide SCHEMBL28787993 | 0.93 | CYP3A4 (0.73) | CYP3A4CYP2C19TSHRPARP1POLB | |
| Benzamide SCHEMBL8632915 | 0.87 | PARP1 (0.89) | CYP3A4CYP2C19TSHRPARP1POLB | |
| Benzamide SCHEMBL3870712 | 0.87 | PARP1 (0.89) | CYP3A4CYP2C19TSHRPARP1POLB | |
| Benzamide SCHEMBL16352 | 0.87 | — | — | |
| Benzamide SCHEMBL1222101 | 0.87 | PARP1 (1.00) | CYP3A4CYP2C19TSHRPARP1POLB | |
| Benzamide SCHEMBL30112947 | 0.87 | PARP1 (1.00) | CYP3A4CYP2C19TSHRPARP1POLB | |
| SCHEMBL21755166 | 0.87 | PARP1 (1.00) | CYP3A4CYP2C19TSHRPARP1POLB | |
| Benzamide SCHEMBL6690447 | 0.87 | PARP1 (1.00) | CYP3A4CYP2C19TSHRPARP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| CN-101910158-A | Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders | ASTRAZENECA AB | 2010-12-08 | — | — | CN | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| EP-2114887-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | Cancer Research Technology Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114887-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | Cancer Research Technology Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114887-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | Cancer Research Technology Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008074997-A8 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER REC TECH LTD (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2008074997-A8 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER REC TECH LTD (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2008074997-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074997-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074997-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | PKD2, PKD1, BAZ2B | CYP3A4 2561/4885CYP2C19 3106/4885TSHR 3813/4885 |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | CYP3A4 590/4885CYP2C19 1027/4885TSHR 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.